Liver Gene & Metabolic Disease Risk: New Discovery
- A gene's role in how the liver manages energy storage could be key to understanding and treating conditions like type 2 diabetes.
- The study found that the PPP1R3B gene determines whether the liver stores energy as glycogen, a form of sugar, or as triglycerides, a type of fat.
- Human genomics studies have linked PPP1R3B gene mutations to metabolic disorders, including type 2 diabetes and fatty liver disease.
Discover how a groundbreaking study unveils the critical role of the PPP1R3B gene in liver energy storage and its link to metabolic disease risk. Penn Nursing researchers have pinpointed that this key gene acts as a metabolic switch, dictating whether the liver stores energy as glycogen or fat.Higher activity favors glycogen, while lower activity increases fat storage, impacting blood sugar and overall health. Gene mutations are associated with type 2 diabetes and fatty liver disease. this research offers exciting insights into the connection between our genes and metabolic health. News Directory 3 has the latest on this and other scientific breakthroughs. Could precision nutrition, tailored to your genetics, be the future of managing metabolic diseases? Discover what’s next in this crucial area of study!
Liver Gene Impacts Energy storage, Diabetes Risk
Updated June 06, 2025
A gene’s role in how the liver manages energy storage could be key to understanding and treating conditions like type 2 diabetes. Research published in Science Advances, led by Kate Townsend Creasy, assistant professor of nutrition science at Penn Nursing, examined the PPP1R3B gene and its function in the liver.
The study found that the PPP1R3B gene determines whether the liver stores energy as glycogen, a form of sugar, or as triglycerides, a type of fat. When the gene is more active, the liver favors glycogen storage. Conversely, lower gene activity leads to increased fat storage.This balance is critical for managing blood sugar and fat levels, impacting overall metabolic health.
Human genomics studies have linked PPP1R3B gene mutations to metabolic disorders, including type 2 diabetes and fatty liver disease. The precise role of the gene in these conditions, though, had remained unclear until this study.
“Our research shows that PPP1R3B is like a control switch in the liver,” Creasy said. “It directs whether the liver stores energy for fast use in the form of glycogen or for longer-term storage as fat.”
Creasy added that the study also revealed changes in how efficiently cells used glucose or fat for energy when the PPP1R3B gene was manipulated. this revelation, she said, could pave the way for new precision nutrition strategies tailored to an individual’s genetics to combat metabolic diseases.
Other contributors to the study include researchers from the Perelman School of Medicine: Minal B. Mehta, Joseph Park, David zhang, Swapnil V. Shewale, Carolin V. Schneider, john S. Millar,Marijana Vujkovic,Nicholas J. Hand, Paul M. Titchenell, Joseph A. Baur, and Daniel J. Rader. The National Institutes of Health provided funding for the research.
What’s next
Further research will explore how manipulating the PPP1R3B gene might offer therapeutic targets for managing type 2 diabetes and fatty liver disease through personalized dietary interventions.